Search research articles
Contact Us
Filters
Showing results (51-60 of 508) with videos related to
Page
of 51
Sort By:
Diabetes, Obesity & Metabolism
|
September 29, 2011
Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes
N A Rhee, T Vilsbøll, F K Knop
Drugs of Today (Barcelona, Spain : 1998)
|
October 3, 2013
Lixisenatide for the treatment of type 2 diabetes
A B Petersen, F K Knop, M Christensen
Expert Opinion on Drug Metabolism & Toxicology
|
October 26, 2012
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
Maria J Jespersen, Filip K Knop, Mikkel Christensen
Endoscopy
|
June 25, 2003
Small-bowel hemangiosarcoma and capsule endoscopy
F K Knop, M B Hansen, S Meisner
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|
March 26, 2011
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review
Katrine B Hansen, Tina Vilsbøll, Filip K Knop
International Journal of Pharmaceutics
|
April 19, 2011
Suspension pellet layering using PVA-PEG graft copolymer as a new binder
L Suhrenbrock, G Radtke, K Knop, et al.
European Journal of Endocrinology
|
April 25, 2014
Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion
David P Sonne, Morten Hansen, Filip K Knop
Current Opinion in Endocrinology, Diabetes, and Obesity
|
January 23, 2022
Long-acting amylin analogues for the management of obesity
David S Mathiesen, Jonatan I Bagger, Filip K Knop
Current Diabetes Reports
|
December 25, 2015
GLP-1 and Amylin in the Treatment of Obesity
T Jorsal, J Rungby, F K Knop, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 24, 2018
New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs
Ida M Gether, Christina Nexøe-Larsen, Filip K Knop
Page
of 51
Search research articles
Search
Showing results (51-60 of 508) with videos related to
Sort By:
Page
of 51
Diabetes, Obesity & Metabolism
|
September 29, 2011
Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes
N A Rhee, T Vilsbøll, F K Knop
Drugs of Today (Barcelona, Spain : 1998)
|
October 3, 2013
Lixisenatide for the treatment of type 2 diabetes
A B Petersen, F K Knop, M Christensen
Expert Opinion on Drug Metabolism & Toxicology
|
October 26, 2012
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
Maria J Jespersen, Filip K Knop, Mikkel Christensen
Endoscopy
|
June 25, 2003
Small-bowel hemangiosarcoma and capsule endoscopy
F K Knop, M B Hansen, S Meisner
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
|
March 26, 2011
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review
Katrine B Hansen, Tina Vilsbøll, Filip K Knop
International Journal of Pharmaceutics
|
April 19, 2011
Suspension pellet layering using PVA-PEG graft copolymer as a new binder
L Suhrenbrock, G Radtke, K Knop, et al.
European Journal of Endocrinology
|
April 25, 2014
Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion
David P Sonne, Morten Hansen, Filip K Knop
Current Opinion in Endocrinology, Diabetes, and Obesity
|
January 23, 2022
Long-acting amylin analogues for the management of obesity
David S Mathiesen, Jonatan I Bagger, Filip K Knop
Current Diabetes Reports
|
December 25, 2015
GLP-1 and Amylin in the Treatment of Obesity
T Jorsal, J Rungby, F K Knop, et al.
The Journal of Clinical Endocrinology and Metabolism
|
August 24, 2018
New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs
Ida M Gether, Christina Nexøe-Larsen, Filip K Knop
Page
of 51